ArticleEuropean journal of human genetics : EJHG2026
Confirmation of frameshift variants in the last exon of FGFR1 as a cause of multiple epiphyseal dysplasia.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomics cycle: discover, diagnose, interpret, act.European journal of human genetics : EJHG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple epiphyseal dysplasia (MED) is a genetically diverse skeletal disorder characterized by abnormal and delayed epiphyseal ossification, early-onset osteoarthritis, joint pain and mild short stature. MED is primarily caused by pathogenic variants in genes involved in cartilage and bone development, including COMP, MATN, COL9A1-3, CANT1 and SLC26A2. FGFR1 was suggested as a cause of MED in a study published in 2020, which reported a frameshift variant in the last exon of this gene. We assembled an international cohort of 13 individuals with MED carrying C-terminal frameshift variants in FGFR1 (NM_023110.3: c.2424_2425del, c.2436_2440del, and c.2460dup). In all three families, the frameshift variants are predicted to result in the same 164-amino acid C-terminal elongation tail. The cohort includes two families (three affected individuals in one, nine in the other) and one previously reported individual. All affected individuals presented with MED without vertebral involvement. Age of symptom onset ranged from 3 to 13 years, with complete penetrance. Genu valgum was very frequent, and most affected patients required its surgical correction. Hypogonadotropic hypogonadism was present in approximately half of the cases. Adult height was mildly reduced, with an median of 164.0 cm in males (-1.7 SDS) and 153.1 cm in females (-1.6 SDS). Structural modeling for the novel C-terminal stretch as a result of the variants could acquire secondary structures, including an α-helix and a β-sheet domain, and could bring a potential antimorphic effect. Our findings confirm FGFR1 C-terminal frameshift variants as a cause of MED and provide further clinical characterization of this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.